Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration.

Due to limited aqueous solubility of dorzolamide at physiologic pH, the pH of Trusopt eye drops (cont. 2% dorzolamide) has to be kept at about 5.65, and to increase the topical bioavailability of the drug from Trusopt the contact time of the drug with the eye surface is increased by increasing the viscosity of the eye drops to 100 cps. This low pH and high viscosity can lead to local irritation. In this study, dorzolamide hydrochloride was formulated as 2% and 4% low viscosity solutions (viscosity 3 to 5 cps) containing randomly methylated beta-cyclodextrin at pH 7.45. These formulations were evaluated in rabbits. The animals were sacrificed at various time points after topical administration of the drug and the dorzolamide concentration determined in the different parts of the eye. Trusopt was used as a reference standard. The topical availability of dorzolamide from the cyclodextrin-containing eye drops appeared to be comparable to that from Trusopt and the drug reached retina and optic nerve to give measurable concentrations for at least 8 h after administration of the eye drops.

[1]  W. Luo,et al.  Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits. , 1995, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[2]  A. Urtti,et al.  OCULAR DISTRIBUTION OF TOPICALLY APPLIED ADRENALINE IN ALBINO AND PIGMENTED RABBITS , 1984, Acta ophthalmologica.

[3]  A. Urtti,et al.  Application site dependent ocular absorption of timolol. , 1988, Journal of ocular pharmacology.

[4]  G. Richard,et al.  Effect of topical dorzolamide on optic nerve head blood flow , 1999, Graefe's Archive for Clinical and Experimental Ophthalmology.

[5]  Josef Flammer,et al.  The effects of antiglaucoma and systemic medications on ocular blood flow , 2003, Progress in Retinal and Eye Research.

[6]  R. Perez,et al.  Dorzolamide effect on ocular blood flow. , 1999, Investigative ophthalmology & visual science.

[7]  T. Maren,et al.  Carbonic anhydrase: General perspective and advances in glaucoma research , 1987 .

[8]  Shulin Ding RECENT DEVELOPMENTS IN OPHTHALMIC DRUG DELIVERY , 1998 .

[9]  A. Canada,et al.  Relationship of viscosity, contact time and prolongation of action of methylcellulose-containing ophthalmic solutions. , 1965, American journal of hospital pharmacy.

[10]  S. Basu,et al.  The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[11]  M. F. Sugrue,et al.  The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. , 1996, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[12]  M. Prausnitz,et al.  Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. , 1998, Journal of pharmaceutical sciences.

[13]  Loftssona,et al.  Cyclodextrins in ophthalmic drug delivery. , 1999, Advanced drug delivery reviews.

[14]  Tomi Järvinen,et al.  Ocular absorption following topical delivery , 1995 .

[15]  M. F. Sugrue Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors , 2000, Progress in Retinal and Eye Research.

[16]  N. Pfeiffer,et al.  Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. , 1997, Survey of ophthalmology.

[17]  T. Maren,et al.  The Development of Topical Carbonic Anhydrase Inhibitors , 1995, Journal of glaucoma.

[18]  A. Harris,et al.  Dorzolamide and ocular blood flow in previously untreated glaucoma patients: a controlled double-masked study. , 2002, Acta ophthalmologica Scandinavica.

[19]  L. Silver Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. , 2000, Survey of ophthalmology.

[20]  A. Urtti,et al.  Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits , 1990 .

[21]  M. Araie,et al.  Beta-adrenergic blockers: ocular penetration and binding to the uveal pigment. , 1982, Japanese journal of ophthalmology.

[22]  T. Maren The General Physiology of Reactions Catalyzed by Carbonic Anhydrase and Their Inhibition by Sulfonamides a , 1984, Annals of the New York Academy of Sciences.

[23]  M. Araie,et al.  Effect of topical dorzolamide on tissue circulation in the rabbit optic nerve head. , 1999, Japanese journal of ophthalmology.

[24]  V. Jäntti,et al.  Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye. II. Drug response , 1984 .

[25]  Indu Pal Kaur,et al.  Acetazolamide: future perspective in topical glaucoma therapeutics. , 2002, International journal of pharmaceutics.

[26]  T. Eysteinsson,et al.  Dorzolamide induces vasodilatation in isolated pre-contracted bovine retinal arteries. , 2004, Experimental eye research.

[27]  E. Stefánsson,et al.  Cyclodextrins in Eye Drop Formulations , 2002 .

[28]  E. Stefánsson,et al.  Optic nerve oxygen tension in pigs and the effect of carbonic anhydrase inhibitors. , 1999, Investigative ophthalmology & visual science.

[29]  A. Urtti,et al.  Minimizing systemic absorption of topically administered ophthalmic drugs. , 1993, Survey of ophthalmology.